FOSTER CITY — Gilead Sciences (GILD) said Friday that an advisory committee in the European Union is recommending that its hepatitis C drug Sovaldi receive marketing approval. The drug is still being reviewed, but the …
However, Gilead Sciences just proved why you can't jump to these sorts of conclusions for this particular industry. …
One part of the market has held on, another part seems to be falling apart. Over the last month or so the S&P 500 and Dow Jones Industrials have essentially moved sideways, but the Nasdaq and Russell 2000 have clearly trended lower. Tech …
It was a busy week as well as weekend for the biotech sector. Highlights from last week include the approval of Gilead’s (GILD) hepatitis C virus (:HCV) treatment, Sovaldi, and that of Auxilium’s (AUXL) Xiaflex (Peyronie’s disease), a …